One subtype includes patients with elevated plasma aldosterone levels, such as those associated with primary aldosteronism, and those who experience “aldosterone escape” or “aldosterone breakthrough” during therapy with ACE inhibitors or ARBs [29]. This evidence concerns the gene ACE and primary aldosteronism.